blank

Dr. Nesrin Aslan

Nuclear Medicine Specialist / Chief Physician

Education

1995 – 1999
Nuclear Medicine Department of Osmangazi University
1986 – 1992
Medical Faculty of Anadolu University

Work Experience

2011 – Now
Neolife Medical Center Nuclear Medicine Specialist / Chief Physician / Operations Manager
2007 – 2011
Kartal Kosuyolu Education and Research Center Nuclear Medicine Department
1999 – 2007
Acıbadem Kadıkoy Hospital Nuclear Medicine Department

Certifications;

2014
JCI Quality Management Systems
2011
Hospital Management Systems (SIEMENS Akademi)
2005
ISO Quality Management Systems

Memberships

  • Turkish Society of Nuclear Medicine
  • OHSAD (Association of Private Hospital and Health Institutions)
  • SASDER (Health Insuriance Associations) 

Scientific Studies

  1. Is there a cut-off value for standardized uptake values in positron emission tomography for predicting response to treatment and survival in patients with advanced non-small cell lung cancer? Single center experience. Oven Ustaalioglu BB, Gumus M, Bilici A, Seker M, Ustaalioglu R, Kefeli U, Salepci T, Canpolat N, Mayadagli A, Dogusoy. J BUON. 2010 Jul-Sep;15(3):529-36.
  2. The role of (18)F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients’ treatment decision making? Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekinsoy B, Ozugur S, Gumus M. Eur J Nucl Med Mol Imaging. 2010 Sep 14.
  3. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management? Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Tekinsoy B, Salepci T, Gumus M. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1259-69. Epub 2010 Mar 23.
  4. F-18 FDG PET/CT imaging in recurrent mantle cell lymphoma presenting with cauda equina syndrome.Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Gumus M.Clin Nucl Med. 2010 Mar;35(3):211-2.
  5. The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma.Ustaalioglu BB, Seker M, Bilici A, Canpolat N, Yıldirim E, Kefeli U, Ustaalioglu R, Yilmaz BE, Salepci T, Ozdemir N, Gumus M. Med Oncol. 2010 Feb 13
  6. Primary non-Hodgkin lymphoma of cervix successfully treated with rituximab: positron emission tomography images before and after therapy: a case report. Ustaalioglu BB, Bilici A, Seker M, Canpolat N, Ozdemir N, Salepci T, Gumus M.Leuk Res. 2010 Apr;34(4):e108-10. Epub 2009 Nov 20.
  7. Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma.Seker M, Bilici A, Ustaalioglu BO, Salman T, Sonmez B, Canpolat NA, Salepci T, Gumus M, Yaylaci M. Leuk Res. 2009 Sep;33(9):e154-6. Epub 2009 Apr 21.
  8. Lesion detectability and clinical effectiveness of dual-head coincidence gamma camera imaging in comparison with dedicated PET systems in tumour patients.Narin Y, Urhan M, Canpolat N, Vardereli E, Bayhan H.J Int Med Res. 2007 Jul-Aug;35(4):467-73.
crossmenuchevron-downarrow-left